2James M,Rae B,Leyland-Jones M,et al.RE:loss of heterozygosity at the CYP2D6locus in breast cancer:implications for germline pharmacogenetic studies[J].J Natl Cancer Inst,2015,107(5):1331-1336. 被引量：1
8Reeves GK,Travis RC,Green J,et al.Incidence of breast cancer and its subtypes in relation to individual and multiple low-penetrance genetic susceptibility loci[J].JAMA,2011,304(4):426-434. 被引量：1
7Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer [ J ].N Engl J Med, 2008,358 (16) :1663 - 1671. 被引量：1
8Baselga J,Tabernero JM. Weekly docetaxel in breast cancer:Applying clinical data to patient therapy [ J ]. The Oncologist, 2001,6 ( suppl 3 ) :26 - 29. 被引量：1
9Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose - dense versus conventionally scheduled and sequential versus concurrent combination chemothera - py as postoperative adjuvant treatment of node -positive primary breast cancer: First report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741 [ J]. Clin Oncol,2003,21 (8) : 1431 - 1439. 被引量：1
10MaisanoR, Mare M, Zavettieri M, et al. Is weekly docetaxelan active and gentle chem - otherapy in the treatment of metastatic breast cancer[ J]. Anticancer Res ,2003,23 (2C) : 1923 - 1926. 被引量：1
